Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purposes

The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.

Methods

A total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6).

Results

Bevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1–37), and median follow-up was 6 months (range 1–36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5–9.5) and 6 months (95 % CI 4.9–7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1–10.9) and 8 months (95 % CI 6.6–9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages.

Conclusions

Present study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:2267–2273

    Article  PubMed  CAS  Google Scholar 

  • Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281–1284

    Google Scholar 

  • Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14

    Article  PubMed  Google Scholar 

  • Cancer Therapy Evaluation Program. Common Terminology Criteria For Adverse Events, version 3, 9 Aug (2006). http://ctepcancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 15 Oct, 2012

  • Demirci U, Yaman M, Buyukberber S, Coskun U, Baykara M, Uslu K et al (2012) Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol 14:546–549

    Article  PubMed  CAS  Google Scholar 

  • Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068–7073

    Google Scholar 

  • Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 14(Suppl 5):v1–49

    Article  PubMed  Google Scholar 

  • Franceschi E, Agati R, Brandes AA (2011) End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Expert Rev Anticancer Ther 11:1713–1717

    Article  PubMed  Google Scholar 

  • Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525

    PubMed  CAS  Google Scholar 

  • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  PubMed  CAS  Google Scholar 

  • Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro-Oncology 14:667–673

    Article  PubMed  Google Scholar 

  • Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A et al (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs 23:659–665

    Article  PubMed  CAS  Google Scholar 

  • Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104:639–646

    Article  PubMed  CAS  Google Scholar 

  • Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D et al (2011) Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 50:630–635

    Article  PubMed  CAS  Google Scholar 

  • Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319–331

    Article  PubMed  CAS  Google Scholar 

  • Kang TY, Jin T, Elinzano H, Peereboom D (2008) Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 89:113–118

    Article  PubMed  CAS  Google Scholar 

  • Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    Article  PubMed  CAS  Google Scholar 

  • Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399–1405

    PubMed  CAS  Google Scholar 

  • Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35

    Article  PubMed  CAS  Google Scholar 

  • Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  • Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T et al (2011) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:143–151

    Article  PubMed  CAS  Google Scholar 

  • Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Presented at: World Federation of Neuro-Oncology Second Quadrennial Meeting. Edinburgh, Scotland, 4–7 May 2005 (Abstract 342)

  • Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB et al (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55:91–100

    Article  PubMed  CAS  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    Article  PubMed  CAS  Google Scholar 

  • Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS (2009) Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11:80–91

    Article  PubMed  CAS  Google Scholar 

  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972

    Article  PubMed  Google Scholar 

  • Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188–e189

    Article  PubMed  Google Scholar 

  • Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578

    PubMed  CAS  Google Scholar 

  • Xu T, Chen J, Lu Y, Wolff JE (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252

    Article  PubMed  Google Scholar 

  • Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ataturk Training and Research Hospital, Bilkent, Ankara, 0906800, Turkey

    Umut Demirci

  2. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey

    Gulnihal Tufan, Yusuf Gunaydin, Ugur Coskun, Suleyman Buyukberber & Mustafa Benekli

  3. Department of Medical Oncology, Marmara University Faculty of Medicine, İstanbul, Turkey

    Bilge Aktas & Faysal Dane

  4. Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

    Ozan Balakan & Alper Sevinc

  5. Department of Medical Oncology, Katip Celebi University Faculty of Medicine, İzmir, Turkey

    Ahmet Alacacioglu

  6. Department of Medical Oncology, Zonguldak Bulent Ecevit University Faculty of Medicine, Zonguldak, Turkey

    Huseyin Engin

  7. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey

    M. Ali Kaplan

  8. Department of Medical Oncology, Numune Training and Research Hospital, Ankara, Turkey

    Nuriye Y. Ozdemir

  9. Department of Medical Oncology, Tepecik Training and Research Hospital, İzmir, Turkey

    I. Tugba Unek

  10. Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey

    Halit Karaca

  11. Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey

    Tulay Akman

  12. Department of Medical Oncology, Sakarya Training and Research Hospital, Sakarya, Turkey

    Ozlem U. Sonmez

  13. Department of Medical Oncology, Inönü University Faculty of Medicine, Malatya, Turkey

    Hakan Harputluoglu

  14. Department of Medical Oncology, Antakya State Hospital, Antakya, Turkey

    Onder Tonyali

Authors
  1. Umut Demirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gulnihal Tufan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bilge Aktas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozan Balakan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmet Alacacioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Faysal Dane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huseyin Engin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Ali Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yusuf Gunaydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nuriye Y. Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. I. Tugba Unek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Halit Karaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tulay Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ozlem U. Sonmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ugur Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hakan Harputluoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Alper Sevinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Onder Tonyali
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Suleyman Buyukberber
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mustafa Benekli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Umut Demirci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demirci, U., Tufan, G., Aktas, B. et al. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol 139, 829–835 (2013). https://doi.org/10.1007/s00432-013-1390-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-013-1390-8

Keywords

Search

Navigation